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A B S T R A C T
The chemotherapeutic agent cisplatin typically induces apoptosis by inhibiting the cell cycle. Cancer Stem Cells
(CSCs), which are a proliferative quiescent and slowly-cycling cell population, are less sensitive and therefore
frequently spared from toxic eﬀects. Thus, it remains a priority to increase the sensitivity of CSCs to cisplatin-
based chemotherapy, or to speciﬁcally target CSCs to improve the therapeutic outcome in breast cancer.
Disulﬁram (DSF) is a drug used clinically for alcoholism treatment that has displayed promising anti-cancer
activity in vitro and in cancer xenografts in breast cancer. Our study provides evidence that DSF inhibits
Aldehyde dehydrogenase (ALDH) enzyme activity, inhibits the expression of stemness-related transcription
factors (Sox, Nanog, Oct) in CSC derived from breast cancer cell lines, and modulates intracellular reactive
oxygen species (ROS) generation. Importantly, our research proved that ALDH+ stem-like cells play important
roles in the resistance to the conventional chemotherapeutic agent cisplatin. DSF enhances the cytotoxic eﬀect of
cisplatin through inhibiting the stemness and by overcoming cisplatin resistance of ALDH+ stem-like cells. A
quantitative measurement showed the synergistic eﬀect of DSF and cisplatin. Further, we show that
ALDH+cancer stem-like cells and ALDH- bulk cancer cells have diﬀerent intrinsic ROS levels, what may explain
diﬀerences in susceptibility to cisplatin treatment. Importantly, this diﬀerence is eliminated by DSF treatment
making both cell types similarly susceptible for cytotoxic eﬀects by cisplatin. These ﬁndings may inﬂuence
chemotherapeutic treatment approaches in the future.
1. Introduction
Breast cancer has become one of the most common malignancies
among the female population and its prevalence has also increased in
women ≤40 years of age [1]. It accounts for 22.9% of all female
cancers worldwide [2]. Despite the impressive clinical improvements of
breast cancer therapies, mortality of breast cancer patients is mostly
related to late diagnosis and resistance to adjuvant systemic therapy,
leading to metastasis and recurrence.
Cancer stem cells (CSCs) are thought to contribute to drug resistance
and cancer recurrence as they are proliferative quiescent and self-re-
newing tumor cell populations. These cells have stem cell character-
istics, and were ﬁrst isolated in breast tumors in 2003 [3]. Conventional
chemotherapies are targeting preferentially the proliferating cancer
cells. However, the undiﬀerentiated populations of CSCs are often un-
aﬀected [4,5] and retain their self-renewal properties. A number of
diﬀerent intrinsic and extrinsic mechanisms have been reported to
correlate with resistance of CSCs, including increased DNA repair
capability, enhanced scavenging of reactive oxygen species (ROS), and
activation of cell survival pathways [6,7]. Thus, it would be promising
to develop alternative adjuvant methods that could target self-renewing
and resistant CSCs directly [8].
ALDH activity has been well-accepted and successfully used as a
CSC marker in a number of solid tumors, including breast, lung, pros-
tate and others [9–11]. Recent studies have demonstrated that ALDH
activity correlates with resistance to both radiation and cisplatin in
vitro [6,12,13]. Cells with higher ALDH activity have enhanced re-
sistance to treatment and maintain their tumorigenic properties
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compared to ALDH negative cells [11]. Additionally, some studies have
shown that ALDH is a ROS scavenger which has the potential to de-
crease oxidative stress and protect stem cells against its toxic eﬀects
[14,15]. Thus, targeting ALDH positive tumor cell subpopulations,
characterized by other biomarkers as CSCs, might provide a new ap-
proach to improve the eﬃcacy of breast cancer treatment.
Currently, cisplatin is one of the most eﬀective chemotherapeutic
agents used for breast cancer treatment. Cisplatin unfolds its cytotoxi-
city by binding to nuclear DNA and thereby interferes with the normal
DNA replication mechanisms [16]. Resistance or insensitivity of tumor
cells to cisplatin treatment is an essential reason causing relapse. The
combination of cisplatin with other chemotherapeutic drugs has ob-
tained satisfactory clinical eﬀects, but also caused greater toxicity for
patients. Thus, it is a signiﬁcant need to explore a combination of cis-
platin with new agents, to overcome chemotherapy resistance while
minimizing their toxic eﬀects on patients.
Disulﬁram (DSF), also known as the medication Antabuse, has been
used to treat alcoholism in patients for more than 60 years [17,18]. DSF
has been demonstrated to have strong anticancer activities in vitro and
in cancer xenografts in breast cancer [19,20]. In the present study, we
explored eﬀects of DSF on ALDH+ stem-like cells and demonstrate a
synergistic eﬀect with cisplatin by diﬀerent mechanisms. This provides
evidence that enhanced therapeutic susceptibility in breast cancer
could be expected.
2. Materials and methods
2.1. Cell culture and drug preparation
Breast cancer cell lines MCF-7, SKB-R3, and MDA-MB-435S were
cultured as adherently growing monolayer cells in DMEM medium with
L-glutamine (Invitrogen, Heidelberg, Germany) supplemented with 10%
fetal bovine serum and 1% penicillin/streptomycin (both from
Biochrom, Berlin, Germany) in a humidiﬁed atmosphere at 37 °C con-
taining 5% CO2. All experiments were performed at a conﬂuency of
around 70%.
Free DSF (Sigma-Aldrich, St. Louis, US) was dissolved in dimethyl
sulfoxide (DMSO, Sigma-Aldrich, St. Louis, US) at a stock concentration
of 10mM, stored at−20 °C and diluted into working concentrations in
medium before use.
2.2. Spheroid formation assay
Adherent monolayer cells were detached with Trypsin/EDTA
(Biochrom) and recultured in Quantum 263 medium (PAA, Cöllbe,
Germany) supplemented with 10 ng/ml Epidermal Growth Factor
(EGF) and 10 ng/ml Fibroblast Growth Factor-basic (bFGF) (Biochrom).
To generate spheroids, single cells were plated in Ultra-Low Attachment
plates (Corning, New York, USA) at a speciﬁc density of 2×104 cells/
ml in the incubator at 37 °C in a humidiﬁed atmosphere with 5% CO2.
2.3. MTT assay
Cells were seeded in 96-well plates at a density of 3000 cells/well in
100 μl medium and allowed to attach overnight. Cells were then treated
with DSF at indicated concentrations for further 72 h. The MTT (Cell
Proliferation Kit I, Roche, Mannheim, Germany) assay was performed
after 72 h incubation to determine cellular proliferation and viability.
Absorbance was measured at wavelength of 590 nm using an enzyme-
linked immunosorbent assay plate reader (BioRad, München,
Germany). Relative viability of cells was calculated as the percentage of
DSF-treated cells from DSF-free control cell cultures.
2.4. Spheroid formation inhibitory assay
To further explore the inhibitory eﬀect of DSF on spheroid
formation, spheroid-derived cells (SDCs) were re-seeded into a 96-well
ultra-low attachment plate at a density of 100 cells or 200 cells in 100 μl
Quantum 263 medium per well (100 cells per well for MCF-7 and SKB-
R3 cell lines; 200 cells per well for MDA-MB-435S cell line). Cells were
exposed to DSF (1 μM or 5 μM) and cultured for 10 days. Cells without
DSF exposure were used as control. Spheroids with 100 μm or more in
diameter were counted and photographed at 50 fold* magniﬁcation.
2.5. Flow cytometric (FACS) analysis of ALDH activity and cell sorting
The identiﬁcation of aldehyde dehydrogenase (ALDH) activity from
spheroid-derived cells (SDCs) and monolayer-derived cells (MDCs) was
conducted using the ALDEFLUOR kit (StemCell Technologies, Köln,
Germany) following the manufacturer’s instructions. For FACS sorting,
SDCs were suspended in PBS buﬀer at a concentration of 1× 107 cells/
ml and sorted on an BD FACSAria II SORP cell sorter (BD Biosciences).
The sorting gates were established with negative controls which were
treated with DEAB.
2.6. Quantitative real-time PCR
Four diﬀerent groups of cells for each breast cancer cell line were
included in this experiment. MDCs and SDCs without any drug treat-
ment cultured for 4 days and then harvested. SDCs treated with DSF
(1 μM) for 48 h and then collected. SDCs exposed to DSF (1 μM) for
48 h, followed by washing and re-cultured in DSF-free medium for
further 48 h, and then collected. Stemness-related nuclear transcription
factor Sox2, Oct3/4, and Nanog were determined in the present study.
MDCs without any drug treatment were used as reference. Primer se-
quences for Oct3/4, Sox2, and Nanog are described in Table 1.
2.7. Apoptosis assessment
Apoptotic status was determined by FLUOS-conjugated Annexin-V
and propidium iodide Kit (Roche, Mannheim, Germany) by ﬂow cyto-
metry on a FACS Calibur following the manufacturer’s instructions.
Brieﬂy, 2*104 cells were seeded in 12-well plates and incubated over-
night. Cells were then treated with drugs at indicated concentration for
further 72 h. All cells were then harvested by trypsinisation and re-
suspended in 100 μl binding buﬀer containing FITC-conjugated
Annexin-V/PI and incubated at RT for 15min. Apoptosis and necrosis
were evaluated using FL3 (PI) and FL1 (Annexin-V) by FACS analysis by
FlowJo software (Treestar, Ashland, OR, USA).
2.8. Flow cytometric analysis of the cell cycle and ROS content
Cells were seeded in 24-well plates at a density of 3×104 cells in
1ml medium per well. After overnight incubation, cells were treated by
indicated concentrations of DSF, or cisplatin, or DSF/cisplatin combi-
nations for 72 h. Cells without treatment were used as controls. Analysis
of cell cycle distribution was performed using ﬂow cytometric analysis
of DNA staining with propidium iodide (PI) [21]. FlowJo software
(Treestar) was used to quantitate the percentage of cells in each cell
cycle phase.
Mitochondrial ROS were measured following the manufacturer’s
instructions of MitoSOX Red kit (Thermo Fisher Scientiﬁc). Samples
Table 1
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without MitoSOX Red Reagent were used to substract background.
Samples treated with MitoSOX Red Reagent, but without any drug
treatment, were used as controls. Mean ﬂuorescence intensity was de-
termined and all samples were normalized to untreated control sam-
ples.
2.9. Statistical analysis
All data presented were representative of three independent ex-
periments. Statistical analyses were performed using GraphPad Prism 6
and FlowJo. The group data were presented as the mean ± standard
error of the mean. Diﬀerences were considered signiﬁcant at P < 0.05.
Quantitative analysis was used for the combination eﬀect to calculate
combination indices (CI) of drugs with CompuSyn software.
3. Results
3.1. Disulﬁram exhibits dose-depend cytotoxicity on breast cancer cell lines
in vitro
To explore the inhibitory eﬀect of DSF in vitro, we initially ex-
amined the cytotoxicity of DSF on three breast cancer cell lines by MTT
assay. As shown in Fig. 1A, no severe cytotoxicity (percentage of cy-
totoxicity< 20%) was observed when cells were exposed to 0.04 μM,
0.2 μM, 1 μM, or 5 μM DSF in MDA-MB-435S and SKB-R3 cell lines. In
MCF-7 cell line, DSF showed mild cytotoxicity at the concentration of
0.04 μM, 0.2 μM, or 1 μM, and a moderate cytotoxicity at a concentra-
tion of 5 μM. However, there was a signiﬁcant decrease in cellular re-
lative viability when the concentration of DSF was increased to 25 μM.
The results indicated that DSF exhibited its cytotoxicity on the in-
vestigated breast cancer cell lines in a dose-dependent manner and at
higher concentrations (> 10 uM).
3.2. DSF inhibits spheroid formation
Spheroid formation assay is a well-accepted assay to enrich for cells
exhibiting positivity for established stem cell markers. As shown in
Fig. 1B and C, 1 μM and 5 μM of DSF were found to be adequate to
inhibit spheroid formation while avoiding too much direct cytotoxicity
on cellular growth. The results showed that the number of spheroids
signiﬁcantly decreased when cells were exposed to 1 μM DSF (the
average spheroid number decreased from 5 to 1 in MCF7, from 5 to 0 in
MDA-MB-435S, and from 3 to 1 in SKB-R3 per x100 seeded). In addi-
tion, the individual size of the spheroids that formed also was reduced
in all cell lines not reaching the cut oﬀ of 100 μM. No growth of
spheroids was observed when the cells were exposed to 5 μM DSF in all
three cell lines investigated. This demonstrated that at this concentra-
tion, despite very low direct toxicity, a stemness inhibitory eﬀect could
be achieved.
3.3. DSF inhibits ALDH activity
To further determine the eﬀective targeting of DSF on stem-like
cells, ALDH activity in both MDCs and SDCs exposed to DSF (10 μM)
was analyzed by ALDEFLUOR assay. As shown in Fig. 2A and B, all
SDCs had an increased proportion of ALDH-positive cells as compared
to parental MDCs by FACS analysis. The proportion of ALDH-positive
cells increased from 10.27 ± 0.636% to 45.7 ± 2.031% in MCF-7,
from 12.13 ± 1.162% to 36.03 ± 2.31% in MDA-MB-435S, from
27.03 ± 0.5783% to 30.65 ± 0.65% in SKB-R3 cell line, in MDC and
SDC, respectively. The proportion of ALDH positive cells was decreased
in both MDCs and SDCs after exposure to DSF: from 10.27 ± 0.636%
to 0.05 ± 0.005% in MDCs and from 45.7 ± 2.031% to
0.4573 ± 0.2022% in SDCs in MCF-7 cell line; from 12.13 ± 1.162%
to 0.033 ± 0.033% in MDCs and from 36.03 ± 2.31% to
0.0171 ± 0.0089% in SDCs in MDA-MB-435S cell line; and from
27.03 ± 0.5783% to 0.04 ± 0.023% in MDCs and from
30.65 ± 0.65% to 1.15 ± 0.055% in SDCs in SKB-R3 cell line. Im-
portantly, the inhibitory eﬀect of DSF was even stronger than the one of
DEAB, used as a control inhibitor, in both MDCs and SDCs. These results
proved that DSF could target cancer stem-like cells in the investigated
cell lines by inhibiting ALDH enzymatic activity.
3.4. DSF inhibits stemness-related gene expression in SDCs
Next, we investigated mRNA expression of nuclear transcription
factors (TF) Sox2, Oct3/4, and Nanog by which CSCs are also sharing
the stemness characteristics of embryonic stem cells. The mRNA levels
detected by RT-PCR of Sox2, Oct3/4, and Nanog were all found to in-
crease in SDCs of all three cell lines from 2-fold to almost 7-fold as
compared to MDCs. The results indicated that spheroids could enrich
cancer stem cells and non-adherent 3D sphere models as well as SDCs
are reasonable to be used for evaluating stem cell activities in these
breast cancer cell lines. After DSF (1 μM) exposure for 48 h, mRNA le-
vels of Sox2, Oct3/4, and Nanog in SDCs were all signiﬁcantly de-
creased, and even lower than those observed in MDCs. Further, the
expression of these markers recovered swiftly when the cells were re-
cultured in DSF-free medium for further 48 h (Fig. 3).
3.5. DSF sensitizes breast cancer cells for cisplatin treatment and acts
synergistically combined with cisplatin
As DSF inhibited the stemness of CSCs, we wanted to further explore
the combination eﬀect of DSF with cisplatin, which rather targets the
proliferating non-stemness cancer cells. We chose to treat the cells with
a low concentration of DSF (1 μM) in order to judge synergistic eﬀects
with cisplatin (used at 5 μM) treatment. As shown in Fig. 4A, the early
and late apoptosis and necrosis together increased from 45.9% by
treatment with cisplatin alone to 61.6% by the cisplatin/DSF combi-
nation treatment in MCF-7 cells, from 19.1%–42.3% in MDA-MB-435S
cells, and from 18.3%–25.2% in SKB-R3 cells, respectively. Our results
revealed that the combination of treatment with cisplatin and DSF in-
duced more cellular apoptosis than either single drug alone. Fig. 4B
shows that cisplatin/DSF combination treatment signiﬁcantly reduced
cell viability compared to cisplatin-treated cells (P < 0.05). Cellular
viability dropped by 50% in MCF-7 cell line, and 20%–30% in MDA-
MB-435S and SKB-R3 cell lines. These results indicate that DSF sensi-
tizes breast cancer cells to cisplatin treatment even at a concentration
where DSF is not toxic by itself.
The combination index (CI) value was used in this study as a
quantitative measurement for drug interaction in terms of synergism
and antagonism for a given endpoint of the eﬀect measurement [22]. CI
＜0.1, CI 0.1−0.3, CI 0.3−0.7, CI 0.7−0.85, CI 0.85−0.9, and CI
0.90–1.10 indicate very strong synergism, strong synergism, synergism,
moderate synergism, slight synergism, and nearly additive eﬀects, re-
spectively [22,23]. As shown in Table 2, the combination of DSF and
cisplatin yielded a synergistic eﬀect in all three tested cell lines at a
broad concentration range from IC50 to IC90. Especially in MCF-7 cells,
the CI value was 0.16 at the IC90 level, and even less than 0.1 at IC50
and IC75 levels, indicating that a strong or very strong synergism was
present. Synergism and moderate synergism were shown on MDA-MB-
435S and SKB-R3 cells, respectively. Dose-reduction index (DRI) values
is a measurement of how many fold the dose of each drug in a sy-
nergistic combination may be reduced at a given eﬀect level when
compared with the doses of each drug alone [22]. The results showed
that the dosage of each drug was reduced by 2-fold to several hundred-
fold when compared with the dosage of each drug alone while main-
taining the equal cytotoxic eﬀect in combinations due to their sy-
nergistic eﬀect.
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3.6. DSF overcomes cisplatin resistance in ALDH+ cells
Since DSF is an irreversible inhibitor of ALDH [24], and ALDH+
stem-like cells may play a role in cisplatin resistance [25], we next
studied whether DSF combined with cisplatin could overcome cisplatin
resistance. ALDH+and ALDH- cells were sorted by ﬂow-cytometry
from MCF-7 and were treated with diﬀerent concentrations of cisplatin
with or without DSF for 72 h, and were then subjected to a MTT assay.
As shown in Fig. 4C and D, there was a signiﬁcant diﬀerence of cellular
viability between ALDH+cells and ALDH- cells when they were
treated with cisplatin alone. ALDH+cells were more resistant to cis-
platin treatment compared with ALDH- cells. However, when a low
concentration of DSF (0.3 μM) was added, cellular viability decreased
signiﬁcantly (around 40%–50%) compared to cells treated with
Fig. 1. Inhibitory eﬀect of DSF on breast cancer cell lines. A). MTT assay. The breast cancer cell lines were exposed to diﬀerent concentrations of DSF for 72 h and
viability related to untreated control. B, C) DSF inhibited spheroid formation. Cells were cultured in 96-well ultra-low attachment plates without or with 1 μM or 5 μM
DSF for 10 days and photographed (magniﬁcation 50-fold *). Spheroids with≥ 100 μm in diameter were counted, and their numbers per well (n=8) were plotted. *
P＜0.05 ** P＜0.01.
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cisplatin only, and there was no diﬀerence between ALDH+ cells and
ALDH- cells anymore, indicating that both ALDH+ cells and ALDH-
cells were equally sensitive to DSF/cisplatin combination treatment.
These results conﬁrmed the potential eﬃcacy of DSF in overcoming the
cisplatin resistance of ALDH+cells in this experimental setting.
3.7. Cell cycle and ROS generation in ALDH+ versus ALDH- cells
To further explore whether DSF has diﬀerent eﬀects on ALDH+and
ALDH- cells, both FACS-sorted ALDH+cells and ALDH- cells were
treated with DSF (0.3 μM) and cisplatin (2 μM). The eﬀect of cisplatin
on cell cycle changes and the eﬀect of DSF on ROS generation was
measured. As shown in Fig. 5A, 5B and 5C, ALDH- cells were more
sensitive to cisplatin treatment, with G0/G1 decreasing from
Fig. 2. DSF inhibits ALDH activity. A) MDC (M) and SDC (S) were exposed to diethylaminobenzaldehyde (DEAB, a speciﬁc ALDH inhibitor, that was used as control),
control medium, or DSF (10 μM), and ALDH activity was detected by ALDEFLUOR assay. Numbers represent ALDH+ cells (%). B) Graphical representation of the
statistical analysis of ALDH activity(n=3). One representative of three independent experiments is shown. * P＜0.05 ** P＜0.01 ***P＜0.001.
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59.4 ± 0.5568% to 39.7 ± 0.7% and G2 increasing from
25.47 ± 0.6173% to 42.17 ± 0.2963%. ALDH+cells were more re-
sistant to cisplatin treatment, with G0/G1 decreasing only from
62.83 ± 1.974% to 59.2 ± 3.126% and G2 increasing from
26.23 ± 1.071% to 27.2 ± 2.053% and there. As shown in Fig. 5D
and 5E, ALDH- cells contained higher levels of ROS mean ﬂuorescence
intensity (MFI) of 229.3 ± 6.566, compared with lower levels of ROS
MFI of 90.73 ± 2.423 in ALDH+cells (P < 0.0001). ROS accumu-
lation was increased in both ALDH+and ALDH- cells when they were
treated with DSF compared to non-drug treated control cells. ROS MFI
by ALDH+ cells and ALDH- cells reached to 524 ± 34.7 and
535 ± 75.26 respectively after DSF treatment and there was no sig-
niﬁcant diﬀerence. Concerning the relative increase, ALDH+cells
showed a greater increase than ALDH- cells as they contain lower basal
levels of ROS.
4. Discussion
In this study, we ﬁrstly conﬁrmed that DSF itself exhibits dose-de-
pendent cytotoxicity in the three breast cancer cell lines investigated.
The ALDH activity was signiﬁcantly inhibited by DSF, supporting a role
for DSF in a targeted treatment of the ALDH positive subpopulation of
CSC. Importantly, a suppressive eﬀect of DSF on stemness of
ALDH+CSC, as shown by inhibition in a sphere formation assay, was
shown. Notably, DSF at 1 μM markedly suppressed the mRNA level of
Oct3/4, Sox2, and Nanog in SDC. We speculate that the decreased ex-
pression of CSC markers could be due to two reasons: ﬁrstly, CSC were
speciﬁcally killed, resulting in the reduction of stemness transcription
factor positive cells in the population, or secondly stemness factor
transcription by CSC was inhibited by DSF while the cells were still
alive and lost their stem cell character. In order to discriminate these
options, we re-cultured the cells for two more days in drug-free fresh
medium after DSF exposure. We found that the expression of CSC
markers quickly recovered after this phase, mostly back to the original
level of SDCs. Since DSF is an irreversible inhibitor of ALDH [24], the
results indicate that the stem cells were not killed at these conditions
during a short term treatment but the stemness characteristics of cells
were rather inhibited.
Next, we explored the combination eﬀect of DSF and cisplatin. This
study demonstrated that DSF sensitized breast cancer cell lines to cis-
platin treatment and the combination treatment induced more cellular
apoptosis than treatment with each drug individually. Our results have
also shown that ALDH+ cells were more resistant to cisplatin treat-
ment than ALDH- cells. This is in agreement with studies from other
labs which demonstrated that cancer cells expressing stem cell markers
are highly resistant to radio- and chemotherapy [26]. Based on these
results, we examined the resistance-reversing eﬀect of DSF in this study.
Our results showed that ALDH+ cells exhibited high sensitivity to
DSF/cisplatin combination treatment, indicating that DSF overcomes
cisplatin resistance. One explanation could be that ALDH activity of
ALDH+cells is inhibited by DSF, leaving ALDH+cells and ALDH-
cells equally sensitive to cisplatin. Thus cisplatin resistance was re-
versed by DSF/cisplatin combination treatment. We used a quantitative
method to determine the combination eﬀect of DSF and cisplatin. The
results showed that DSF and cisplatin yielded a synergistic eﬀect at
broad eﬀect levels ranging from IC50 to IC90 in all three breast cancer
cell lines. This synergistic eﬀect in a DSF/cisplatin combination may
provide many therapeutic beneﬁts in clinical treatment regimens
against breast cancer. The most important consequence is that it could
increase or at least maintain the same eﬃcacy but decrease the dosage
of each drug to reduce toxicity, thereby potentially reducing the toxi-
city toward normal tissues.
To explore the possible mechanism of DSF and cisplatin in combi-
nation treatment, cell cycle analysis and ROS generation was de-
termined in this study. Studies have shown that cisplatin induces cross-
linking of DNA [16], therefore inducing a G2/M arrest. Our results also
showed that cisplatin arrested cell cycle distribution in the G2 phase.
However, DSF had no signiﬁcant eﬀect on cell cycle distribution. Cell
cycle arrest in DSF/cisplatin combination was mainly due to the cis-
platin eﬀect. The results showed that DSF exerted its cytotoxicity by
inducing ROS accumulation in a dose-dependent and time-dependent
manner. Interestingly, high concentrations of DSF could also induce
ROS accumulation in a very short time interval of hours, indicating that
DSF can cause instant killing of cells via ROS [27]. In the DSF/cisplatin
combination treatment at high concentration in a short time period,
DSF was responsible for most of the ROS accumulation. Lower con-
centration of DSF needed longer time to induce cells to accumulate
ROS, and both DSF and cisplatin contributed to the ROS accumulation
at lower concentration of the drug combinations.
The eﬀect of cisplatin on cell cycle distribution and the eﬀect of DSF
on ROS accumulation was further determined after cell sorting. The
results indicated that ALDH+ cells showed cancer stem-like properties,
with low levels of ROS, while ALDH- cells were more proliferating with
higher levels of ROS due to rapid metabolism. Upon treatment, more
ROS accumulated in ALDH+ cells, ultimately reaching the same levels
of ROS as in ALDH- cells. These results indicated that DSF conferred an
equal cytotoxicity to ALDH+and ALDH- cells. Concerning the relative
increase, however, ALDH+cells showed a greater increase than ALDH-
Fig. 3. DSF inhibits mRNA expression of stemness-related transcription factors.
The expression of stemness-related TF in MDC, SDC, DSF-treated SDC (1 μM,
48 h), and SDC treated by DSF-recultured (1 μM, 48 h, followed by a chase to
reculture in DSF-free medium for further 48 h) was quantiﬁed by qRT-PCR. M:
MDC; S: SDC. One representative of three independent experiments is shown. *
P＜0.05.
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cells as they contain lower basal levels of ROS, indicating that
ALDH+cells might be more sensitive to DSF treatment or have less
compensatory scavenging possibilities.
In consideration of all results we got in this study, we summarize the
possible mechanisms for the synergistic eﬀect of DFS and cisplatin
combination as follows: 1) DSF suppresses ALDH activity and stemness,
reverses cisplatin resistance on ALDH+cells, and sensitizes a cisplatin-
resistant CSC population to cisplatin treatment, consequently im-
proving the ability of cisplatin to kill resistant or less sensitive cancer
cells. This is in agreement with a study by Song et al. [28] that DSF
Fig. 4. Combination eﬀect of DSF with cis-
platin. A) Flow cytometric analysis of an
apoptosis assay. Cells were exposed to DSF
(1 μM), Cisplatin (5 μM), or DSF (1 μM) plus
Cisplatin (5 μM) for 48 h and the percentage of
apoptotic cells was determined by Annexin-V/
PI dual staining by ﬂow cytometric analysis.
Percentage of cells were determined in the four
quadrants: live cells, (Annexin-V−/PI-, lower/
left quadrant); early apoptotic cells (Annexin-V
+/PI−, lower/right quadrant); late apoptotic
cells (Annexin-V+/PI+, upper/right quad-
rant); and necrotic cells (Annexin-V−/PI+,
upper/left quadrant), respectively. B)
Graphical representation of the statistical ana-
lysis of the Annexin-V/PI dual staining results.
C) DSF sensitizes breast cancer cells for cis-
platin treatment. MCF-7, MDA-MB-435S and
SKB-R3 cells were treated with cisplatin alone
or with cisplatin/DSF combination at indicated
concentrations for 72 h, followed by MTT assay
for cellular viability. D, E) DSF overcomes cis-
platin resistance on ALDH+ cells. ALDH+/-
cells from MCF-7 were treated with (D) cis-
platin alone, (E) cisplatin/DSF or DSF at in-
dicated concentrations for 72 h. Cellular viabi-
lity was determined by MTT assay. Cells
without any drug treatment were used as con-
trol. One representative of three independent
experiments is shown. * P＜0.05 ** P＜0.01.
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improved the eﬀectiveness of cisplatin in resistant lung cancer cell
lines. 2) DSF and cisplatin exert their cytotoxicity based on diﬀerent
mechanisms. DSF induces cellular apoptosis by accumulation of ROS,
including instant killing and delayed cytotoxicity, while cisplatin in-
duces apoptosis based on DNA damage, leading to cell cycle distribu-
tion changes, and increased ROS generation during longer treatment
periods. 3) Cisplatin and DSF exert their cytotoxicity on diﬀerent tar-
geted cell types. The conventional chemotherapy agent cisplatin targets
proliferating cells with little eﬀect on CSCs, while DSF is equally cy-
totoxic to both proliferating cells and ALDH+ stem-like cells and ren-
ders CSCs more sensitive to DSF/cisplatin treatment. Taken together,
this study provides evidence that DSF may be used as a novel adjuvant
and could be tested for incorporation into conventional chemotherapy
regimens, to improve the eﬃcacy of targeted chemotherapy for breast
cancer treatment in future.
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Computer-simulated CI and DRI values for drug combinations at diﬀerent levels
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Cis+DSF Combination Combination Index
at
Dose-Reduction Index at
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a fold reduction compared to single dose cisplatin.
b fold reduction compared to single dose DSF.
Fig. 5. Cell cycle analysis and ROS production of ALDH+and ALDH- cells by FACS. A) The eﬀect of cisplatin (2 μM, 72 h) on cell cycle alterations in ALDH+/- cells.
B,C) Graphical representation of the percentage of cells in each cell cycle phase was quantitated and analyzed (n=3) D) The eﬀect of DSF (0.3 μM, 72 h) on ROS
production in ALDH+/- cells. Comparison of a) ALDH+/- control; b) ALDH+DSF-treated/control; c) ALDH- DSF-treated/control; d) ALDH+/- DSF-treated. E)
Graphical representation of the ROS mean ﬂuorescence intensity (MFI) was quantitated and analyzed (n=3) One representative of three independent experiments is
shown * P＜0.05 **P＜0.01 *** P＜0.001 ****P＜0.0001.
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